全文获取类型
收费全文 | 1654篇 |
免费 | 100篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 44篇 |
妇产科学 | 24篇 |
基础医学 | 208篇 |
口腔科学 | 13篇 |
临床医学 | 233篇 |
内科学 | 357篇 |
皮肤病学 | 24篇 |
神经病学 | 125篇 |
特种医学 | 57篇 |
外科学 | 370篇 |
综合类 | 4篇 |
预防医学 | 83篇 |
眼科学 | 27篇 |
药学 | 72篇 |
肿瘤学 | 132篇 |
出版年
2023年 | 16篇 |
2022年 | 34篇 |
2021年 | 75篇 |
2020年 | 32篇 |
2019年 | 50篇 |
2018年 | 65篇 |
2017年 | 36篇 |
2016年 | 42篇 |
2015年 | 39篇 |
2014年 | 60篇 |
2013年 | 68篇 |
2012年 | 112篇 |
2011年 | 93篇 |
2010年 | 59篇 |
2009年 | 35篇 |
2008年 | 72篇 |
2007年 | 93篇 |
2006年 | 79篇 |
2005年 | 63篇 |
2004年 | 58篇 |
2003年 | 56篇 |
2002年 | 53篇 |
2001年 | 59篇 |
2000年 | 39篇 |
1999年 | 48篇 |
1998年 | 17篇 |
1997年 | 14篇 |
1996年 | 22篇 |
1995年 | 18篇 |
1994年 | 14篇 |
1993年 | 7篇 |
1992年 | 30篇 |
1991年 | 32篇 |
1990年 | 33篇 |
1989年 | 30篇 |
1988年 | 19篇 |
1987年 | 19篇 |
1986年 | 19篇 |
1985年 | 18篇 |
1984年 | 20篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1974年 | 5篇 |
1972年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有1818条查询结果,搜索用时 15 毫秒
41.
42.
43.
Astrid Godron Jér?me Harambat Valérie Boccio Anne Mensire Adrien May Claire Rigothier Lionel Couzi Benoit Barrou Michel Godin Dominique Chauveau Stanislas Faguer Marion Vallet Pierre Cochat Philippe Eckart Geneviève Guest Vincent Guigonis Pascal Houillier Anne Blanchard Xavier Jeunemaitre Rosa Vargas-Poussou 《Clinical journal of the American Society of Nephrology》2012,7(5):801-809
44.
Henri S Siret C Machy P Kissenpfennig A Malissen B Leserman L 《European journal of immunology》2007,37(5):1184-1193
Skin-draining LN contain several phenotypically distinguishable DC populations, which may be immature or mature. Mature DC are generally considered to have lost the capacity to acquire and present newly encountered Ag. Using antibody-opsonized liposomes as Ag carriers, we show that mature DC purified from skin explants are able to efficiently capture liposomes, process Ag encapsulated within them and activate Ag-specific CD4(+) T cells. Explant DC from mice with Langerhans cells (LC) expressing the primate diphtheria toxin receptor that were exposed to diphtheria toxin in vivo presented Ag as well as explant DC from wild-type mice, indicating that LC are not required and dermal DC are probably responsible for this presentation. We further show that all DC subtypes from LN that capture opsonized Ag are capable of cross-presenting it to CD8(+) T cells. Induction of additional maturation in vivo by LPS or treatment with double-stranded RNA did not alter the Ag presentation capacity of the skin or LN DC subtypes. These results suggest that mature DC present in skin-draining LN may play an important role in the induction of primary and/or secondary immune responses against Ag delivered to the LN that they take up by receptor-mediated endocytosis. 相似文献
45.
46.
47.
Jenna Anderson Sara Hägglund Emmanuel Bréard Mickaël Riou Siamak Zohari Loic Comtet Ann-Sophie Olofson Robert Gélineau Guillaume Martin Marianne Elvander Gunilla Blomqvist Stéphan Zientara Jean Francois Valarcher 《Vaccine》2014
Bluetongue virus (BTV) infections in ruminants pose a permanent agricultural threat since new serotypes are constantly emerging in new locations. Clinical disease is mainly observed in sheep, but cattle were unusually affected during an outbreak of BTV seroype 8 (BTV-8) in Europe. We previously developed an experimental vaccine based on recombinant viral protein 2 (VP2) of BTV-8 and non-structural proteins 1 (NS1) and NS2 of BTV-2, mixed with an immunostimulating complex (ISCOM)–matrix adjuvant. We demonstrated that bovine immune responses induced by this vaccine were as good or superior to those induced by a classic commercial inactivated vaccine. In this study, we evaluated the protective efficacy of the experimental vaccine in cattle and, based on the detection of VP7 antibodies, assessed its DIVA compliancy following virus challenge. Two groups of BTV-seronegative calves were subcutaneously immunized twice at a 3-week interval with the subunit vaccine (n = 6) or with adjuvant alone (n = 6). Following BTV-8 challenge 3 weeks after second immunization, controls developed viremia and fever associated with other mild clinical signs of bluetongue disease, whereas vaccinated animals were clinically and virologically protected. The vaccine-induced protection was likely mediated by high virus-neutralizing antibody titers directed against VP2 and perhaps by cellular responses to NS1 and NS2. T lymphocyte responses were cross-reactive between BTV-2 and BTV-8, suggesting that NS1 and NS2 may provide the basis of an adaptable vaccine that can be varied by using VP2 of different serotypes. The detection of different levels of VP7 antibodies in vaccinated animals and controls after challenge suggested a compliancy between the vaccine and the DIVA companion test. This BTV subunit vaccine is a promising candidate that should be further evaluated and developed to protect against different serotypes. 相似文献
48.
Antoine Néel Benoit Henry Sebastien Barbarot Agathe Masseau François Perrin Claire Bernier Xavier Kyndt Xavier Puechal Pierre-Jean Weiller Olivier Decaux Jacques Ninet Arnaud Hot Achille Aouba Leonardo Astudillo Jean-Marie Berthelot Fabrice Bonnet Jean-Marie Brisseau Bérangère Cador Fabienne Closs-Prophette Thomas Dejoie Jean-Dominique de Korwin Robin Dhote Renato Fior Bernard Grosbois Eric Hachulla Pierre-Yves Hatron Henry Jardel David Launay Adrien Lorleac'h Pierre Pottier Guillaume Moulis Jacques Serratrice Amar Smail Mohamed Hamidou 《Autoimmunity reviews》2014,13(10):1035-1041
The aim of this study is to assess the long-term effectiveness and safety of IL1Ra in Schnitzler syndrome (SchS). Between 2010 and 2012, we performed a nationwide survey among French internal medicine departments to identify SchS patients. We retrospectively analyzed the long-term efficacy and safety of IL1Ra and the outcome of patients that did not receive this treatment. Forty-two patients were included in the study, 29 of whom received IL1Ra. The mean age at disease onset was 59.9 years. Disease manifestations included urticaria (100%), fever (76%), bone/joint pain (86%), bone lesions (76%), anemia (67%), and weight loss (60%). The monoclonal gammopathy was overwhelmingly IgM kappa (83%). The mean follow-up was 9.5 years (range: 1.6-35). Two patients developed Waldenström's macroglobulinemia and one developed AA amyloidosis. All of the 29 patients who received IL1Ra responded dramatically. After a median follow-up of 36 months (range: 2-79), the effectiveness remained unchanged. All patients remained on anti-IL-1 therapy. Twenty-four patients (83%) went into complete remission and five (17%) into partial remission. Three patients experienced grade 3-4 neutropenia. Six patients developed severe infections. No lymphoproliferative diseases occurred while on IL1Ra. When last seen, all patients without anakinra had an active disease with variable impact on their quality of life. Their median corticosteroids dosage was 6 mg/d (range: 5-25). IL1Ra is effective in SchS, with a sharp corticosteroid-sparing effect. Treatment failures should lead to reconsider the diagnosis. Long-term follow-up revealed no loss of effectiveness and a favorable tolerance profile. The long-term effects on the risk of hemopathy remain unknown. 相似文献
49.
50.